Side-by-side · Research reference
HexarelinvsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed19/45 cited
BFDA-ApprovedVerified15/53 cited
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Hexarelin
Semaglutide
Primary target
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes initially; tachyphylaxis with chronic useGhigo 1997
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
Hexarelin
Semaglutide
Frequency
1–2× per day max (tachyphylaxis with chronic 3× daily)
Once weekly, same day each week
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 / Phase 2 trialsSmith 1996Ghigo 1997
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Duration
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Indefinite for chronic indication
Discontinuation results in weight regain.
Reconstitution
Bacteriostatic water
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
Pre-sleep + fasted preferred
Any time of day, with or without food
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
04Side Effects & Safety
Parameter
Hexarelin
Semaglutide
Hunger
Strong appetite increase via ghrelin agonism
—
IGF-1 elevation
Strong; monitor with chronic high-dose use
—
Cancer risk
Contraindicated in active malignancy (GH/IGF-1 axis)
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
Hexarelin
Semaglutide
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Injection site
SQ — abdomen or thigh. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Timing
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Needle
29–31G, 4–8 mm insulin syringe.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)